The US Food and Drug Administration (FDA) has approved Janssen Therapeutics' NS3/4A protease inhibitor 'Olysio (simeprevir)' for the treatment of chronic hepatitis C infection as part of an antiviral treatment regimen in combination with ...
Myriad Genetics, a molecular diagnostic company, and biotechnology firm BioMarin Pharmaceutical have signed a research collaboration agreement for identifying tumor types that may be sensitive to BioMarin's investigational product ...
Tags: Myriad Genetics, Biomarin
A.P. Pharma, a specialty pharmaceutical company, has initiated a program to expand its pipeline of sustained release products, including a new program targeting the relief of post-surgical pain. The company also announced it will pursue a ...
Tags: A.P.Pharma, Pipeline Expansion
US-based biotechnology firm Ignyta has entered into a license agreement with Nerviano Medical Sciences (Nerviano), under which Ignyta will get exclusive global development and marketing rights of tyrosine kinase inhibitors RXDX-101 and ...
Tags: Ignyta, Tyrosine Kinase Inhibitors
Synta Pharmaceuticals has announced the publication of the company's first patent application covering its proprietary Hsp90-inhibitor drug conjugate (HDC) platform, which leverages the company's expertise in chaperone biology and medicinal ...
Calithera Biosciences has completed a $35m series D financing led by Adage Capital Partners, LP. Joining Adage as new investors in this financing are the Longwood Fund and two other institutional investor groups. The transaction also ...
US-based Loxo Oncology has announced that its lead clinical program is a potent and selective inhibitor of the Trk family of receptor tyrosine kinases. Loxo Oncology acquired rights to this program from Array Biopharma, which had pursued ...
Tags: Loxo Oncology, Medicine
The US FDA's Antiviral Drugs Advisory Committee has recommended approval for Medivir's investigational protease inhibitor simeprevir (TMC435) 150mg capsules for the treatment of genotype 1 chronic hepatitis C in adult patients with ...
Tags: Medivir, Hepatitis C Patients
Alzheon announced the launch of the company, the securing of initial private financing, and the signing of an exclusive license agreement to a novel clinical drug candidate for Alzheimer’s disease, a family of analogs, and a drug ...
Tags: Alzheon, Alzheimer's Disease
Cortec Corporation, a world leader in innovative, green, sustainable technologies has spent many years of dedicated experimentation to develop eco-efficient, biodegradable products made from sustainable materials that have positive effects ...
US-based pharmaceutical firm Merck has received Breakthrough Therapy designation from the US Food and Drug Administration (FDA) for its investigational oral combination regimen MK-5172/MK-8742 for the treatment of chronic hepatitis C virus ...
Cortec Corporation has launched EcoLine 3680, a certified biobased, biodegradable, ready-to-use temporary coating for multimetal protection. EcoLine 3680 is formulated with USDA. A renewable raw materials; which allows use for corrosion ...
Danish pharmaceutical firm Novo Nordisk has received biologics licence application (BLA) approval from the US Food and Drug Administration (FDA) for its recombinant coagulation factor VIII, Novoeight. Novoeight is intended for adults and ...
Tags: Novo Nordisk, Drug
Janssen-Cilag (Janssen) has submitted a marketing authorization application to the European Medicines Agency (EMA) for the approval of a once-daily fixed-dose antiretroviral combination tablet of HIV-1 medicine darunavir with cobicistat. ...
Tags: European Marketing, HIV-1
Boehringer Ingelheim has submitted a marketing authorisation application to the European Medicines Agency (EMA) for the approval of its oral triple angiokinase inhibitor nintedanib. Nintedanib to be used in combination with docetaxel is ...
Tags: Boehringer Ingelheim, Lung Cancer